Mifepristone: where do we come from and where are we going?

review OA: closed CC0 ⤵ 12 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
AI-generated summary by claude@2026-06, 2026-06-07

This review discusses the historical development, current applications, and future research directions for mifepristone, a medication used primarily for medical abortion and Cushing's syndrome.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

Mifepristone Mifepristone Mifepristone Mifepristone Receptors, Progesterone Abortifacient Agents, Steroidal Abortifacient Agents, Steroidal Abortifacient Agents, Steroidal Abortifacient Agents, Steroidal Abortion, Legal Animals Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Contraceptives, Postcoital, Synthetic Contraceptives, Postcoital, Synthetic Contraceptives, Postcoital, Synthetic Contraceptives, Postcoital, Synthetic Female

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (12)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:17:00.782903+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK